BioXcel Therapeutics BTAI

$ 0.34 8.12%

Quarterly report 2024-Q3
added 11-14-2024

BioXcel Therapeutics Balance Sheet 2011-2024 | BTAI

Annual Balance Sheet BioXcel Therapeutics

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-232 M	-212 M	-31.4 M	-42.6 M	-516 K	-	-	-	-	-	-
Long Term Debt	101 M	93.1 M	1.1 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	346 K	-	-	237 K	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	1.4 M	1.03 M	-	-	-	-	-	-	-	-
Total Current Liabilities	27.3 M	32.9 M	16.7 M	11.8 M	8.47 M	4.66 M	-	-	-	-	-	-	-
Total Liabilities	130 M	129 M	17.8 M	13.2 M	9.5 M	4.66 M	2.34 M	331 K	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-591 M	-412 M	-246 M	-139 M	-56.7 M	-23.7 M	-4.45 M	-	-	-	-	-	-
Total Assets	73.7 M	206 M	239 M	220 M	36.4 M	43.5 M	1.36 M	7 K	-	-	-	-	-
Cash and Cash Equivalents	65.2 M	194 M	233 M	213 M	32.4 M	42.6 M	887 K	-	-	-	-	-	-
Book Value	-56.5 M	76.8 M	222 M	207 M	26.9 M	38.9 M	-982 K	-324 K	-	-	-	-	-
Total Shareholders Equity	-56.5 M	76.8 M	222 M	207 M	26.9 M	38.9 M	-982 K	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet BioXcel Therapeutics

	2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	104 M	103 M	101 M	99.1 M	96.8 M	-	93.1 M	91.7 M	61.1 M	1.03 M	1.1 M	1.18 M	1.26 M	1.33 M	1.4 M	1.4 M	1.4 M	1.4 M	1.03 M	1.03 M	1.03 M	1.03 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	135 M	140 M	130 M	141 M	134 M	-	129 M	118 M	84 M	17 M	17.8 M	15.8 M	13.7 M	13.7 M	13.2 M	13.2 M	13.2 M	13.2 M	9.5 M	9.5 M	9.5 M	9.5 M	4.66 M	4.66 M	4.66 M	4.66 M	2.34 M	2.34 M	2.34 M	2.34 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-639 M	-626 M	-591 M	-568 M	-518 M	-	-412 M	-357 M	-315 M	-277 M	-246 M	-220 M	-193 M	-165 M	-139 M	-139 M	-139 M	-139 M	-56.7 M	-56.7 M	-56.7 M	-56.7 M	-23.7 M	-23.7 M	-23.7 M	-23.7 M	-4.45 M	-4.45 M	-4.45 M	-4.45 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	48.9 M	65.4 M	73.7 M	100 M	140 M	-	206 M	245 M	248 M	211 M	239 M	261 M	281 M	200 M	220 M	220 M	220 M	220 M	36.4 M	36.4 M	36.4 M	36.4 M	43.5 M	43.5 M	43.5 M	43.5 M	1.36 M	1.36 M	1.36 M	1.36 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	40.4 M	56.3 M	65.2 M	90 M	128 M	-	194 M	232 M	233 M	200 M	233 M	253 M	273 M	194 M	213 M	213 M	213 M	213 M	32.4 M	32.4 M	32.4 M	32.4 M	42.6 M	42.6 M	42.6 M	42.6 M	887 K	887 K	887 K	887 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-85.6 M	-74.3 M	-56.5 M	-40.6 M	5.86 M	-	76.8 M	127 M	164 M	194 M	222 M	246 M	267 M	187 M	207 M	207 M	207 M	207 M	26.9 M	26.9 M	26.9 M	26.9 M	38.9 M	38.9 M	38.9 M	38.9 M	-982 K	-982 K	-982 K	-982 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-85.6 M	-74.3 M	-56.5 M	-40.6 M	5.86 M	53 M	76.8 M	127 M	164 M	194 M	222 M	246 M	267 M	187 M	207 M	207 M	207 M	207 M	26.9 M	26.9 M	26.9 M	26.9 M	38.9 M	38.9 M	38.9 M	38.9 M	-982 K	-982 K	-982 K	-982 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency